Transfer

A research team from Helmholtz Munich, the Technical University of Munich (TUM) and the TUM University Hospital has developed DeepNeo, an AI-powered algorithm that automates the process of analyzing coronary stents after implantation. The tool…

The Helmholtz Association is pooling its commitment to prevention research with the launch of the Helmholtz Health Prevention Task Force. In a strategy paper published in Nature Medicine, the expert committee outlines initial concepts for more…

EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV). The aim is to protect people from a range of serious…

In 2021, a research team led by Prof. Heiko Lickert from Helmholtz Munich discovered the insulin-inhibitory receptor "Inceptor" and its role as a suppressor of the insulin signaling pathway. Now, the researchers have unlocked another, even more…

The Life Science Factory has opened its new site on the Helmholtz campus in Munich. Beginning in 2025, around 1,800 square meters of state-of-the-art laboratories and a flexible co-working space will be available for life science start-ups and…

On June 12, 2024, the National Strategy for Gene and Cell Therapies was unveiled at the Futurium in Berlin.

In an ongoing phase 1 clinical trial targeting malignant glioblastoma, the initial patient has received a dosage of a novel drug candidate, derived from an antibody originating at Helmholtz Munich. This innovative compound, coupled with a…

In a new collaboration, the Computational Health Center at Helmholtz Munich has teamed up with the global pharmaceutical company Pfizer. The joint initiative, spanning three years, aims to leverage Pfizer's vast knowledge and accumulated data in…

EU Project PerForM-REACT Strengthens Pandemic Preparedness Efforts

On March 11, 2024, the inauguration of the expanded safety laboratory in Augsburg marked a milestone within the EU-funded "PerForM-REACT" project, aimed at enhancing pandemic…

TherVacB, a novel therapeutic vaccine to combat chronic hepatitis B, entered the first clinical trial. The vaccine was designed and developed under the leadership of Helmholtz Munich. This phase 1a clinical trial is conducted at the Division of…

2023 has changed the way we treat obesity. A new class of drugs, mimicking a gut hormone called glucagon-like peptide-1 (GLP-1), is reshaping medicine and improving many people’s lives globally. GLP-1 drugs do not only induce significant weight loss,…

Innovations and transfer are specifically promoted at Helmholtz Munich.

In collaboration with Helmholtz Munich, Medigene is expanding its portfolio of costimulatory switch proteins in the field of cancer immunotherapy. By expanding the license field, these specialized proteins, initially developed by Helmholtz Munich,…

The Life Science Factory incubator initiated by Sartorius in Göttingen and the top biomedical research center Helmholtz Munich are entering into a strategic partnership to support spin-offs in the life sciences. Within this framework, the Life…

"M1 - Munich Medicine Alliance" established as a strategic alliance for excellence in healthcare in Munich.

The Helmholtz Pioneer Campus was officially inaugurated today under the slogan "ENGINEERING THE FUTURE OF MEDICINE". Commissioning this new state-of-the-art research facility is a significant milestone for young talents in medical research and…

Prof. Reinhard Zeidler about hope in the fight against glioblastoma, the most common and malignant form of brain tumor and how he accelerates the development of antibodies into application.

Helmholtz Munich and Medigene AG expand their partnership in order to further discover and develop T-cell immunotherapies for solid tumors. Medigene acquired from Helmholtz Munich the exclusive, worldwide rights to the CD40L-CD28 Costimulatory Switch…

Clinical trials are a milestone in the development of safe and effective drugs and therapies. An antibody developed by Helmholtz Munich is now entering a phase 1 clinical trial. Together with the radiopharmaceutical company ITM Isotope Technologies…

Matthias Tschöp, CEO of Helmholtz Munich, talks about translating scientific discoveries into clinical practice, about ambitious targets, and about ideas he acquired during his time in the USA.

The medical technology company Dermagnostix GmbH is a joint spin-off of Helmholtz Munich, the Technical University (TU) Munich and Hahn-Schickard. Its goal: to redefine molecular diagnostics in dermatology. Dermagnostix has now qualified as one of 30…

Researchers at Helmholtz Munich are working toward a world without diabetes. They are not doing so alone, but with a network of organizations, hospitals, and pharmaceutical companies. Their goal is to use experts’ knowledge to create something new:…

A team of researchers from Helmholtz Munich, the German Center for Diabetes Research (DZD) and Novo Nordisk have developed a new hormone combination for the future treatment of type 2 diabetes. The scientists have combined the blood sugar-reducing…

A clinical study confirms the success of a novel technology developed by Helmholtz Munich and the Technical University of Munich (TUM) for the evaluation of the treatment of psoriasis. With the new method, doctors can look deeper into the skin of…

The Epstein-Barr virus (EBV) has been known for some time to play a part in a range of diseases. A current US study has now shown a close link between EBV and multiple sclerosis. Scientists at Helmholtz Munich and DZIF are already working on…

Researchers have designed antibodies as novel therapeutic candidates for the treatment of chronic hepatitis B and hepatocellular carcinoma. Their study in human cell cultures and in living mice showed the elimination of antigen-positive cells and…

A newly engineered organoid on chip platform mimics robustly key features of human pancreas development. This is a stepping stone towards reliable diagnostic solutions for early-stage pancreatic cancer. The study was carried out by an…

A small molecule has entered a novel clinical trial for cancer immunotherapy. The molecule inhibits an enzyme called MALT1 that plays a critical role in suppressing immune reactions against tumor cells. Preclinical studies showed that blocking MALT1…

Helmholtz Zentrum München and Novo Nordisk recently extended their multi-year strategic partnership which aims to identify and jointly develop novel targets and enabling technologies, ultimately supporting the development of innovative medicines for…

Researchers at Helmholtz Zentrum München and the University of Bochum received this year's Erwin Schrödinger Prize in recognition of their efforts to develop a cure for parasitic diseases such as Chagas disease with a new compound. The prize is…

The Helmholtz Zentrum München teams up with Boehringer Ingelheim in an endeavor to identify novel candidates for anti-obesity treatment.

Large-scale antibody testing against the new coronavirus SARS-CoV-2 could help to obtain reliable data on infection rates. Screening children for early stages of type 1 diabetes in Bavaria, "Fr1da-plus" will now integrate SARS-CoV-2 antibody testing…

Helmholtz Zentrum München and academic partners in the US entered into an exclusive license agreement with Arbormed towards further developing and globally commercializing a potential drug for the treatment of Wilson disease.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it has reached a new…

Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B. The scientists found that the large amount of…

On April 8, 2025, more than 330 individuals affected by lung diseases – as well as their families – participated in the online Lung Patient Forum. The event offered attendees the opportunity to submit questions directly to leading pulmonary experts,…

On Girls’ Day 2025, Helmholtz Munich opens its laboratories to welcome 25 female students for an exciting day as young researchers. Three of our research institutes provide exclusive insights into their work, demonstrating how science helps us better…

On March 11th, Helmholtz Munich brought together successful and inspiring women from science and business for a dynamic exchange on leadership.

In line with World Obesity Day, the Helmholtz Munich information portal diabinfo.de now provides comprehensive new information on obesity. In addition to content on the prevalence, risk factors, causes, and diagnosis of obesity, the portal also…

To mark the International Day of Women and Girls in Science, Helmholtz Munich has opened the exhibition STEM Passion at the Helmholtz Pioneer Campus. The exhibition celebrates the achievements of outstanding female scientists and highlights the…

Helmholtz Munich has been awarded the "Shaping Diversity" certificate by the Stifterverband. This recognition honors the research institution's commitment to embracing diversity as an opportunity and leveraging it for organizational development.

The earlier people start practicing a healthy lifestyle, the greater the benefits. This is why children and young people in particular should be strengthened in their health literacy - this is the central goal of the clever.gesund program. After a…

Do you know how powerful your body is? Dive into this question and more at “Stem Cells, the Genies of the Body,” an interactive exhibition opening at the Deutsches Museum’s Science Communication Lab. Created by scientists from the Helmholtz Munich…

In recognition of World Diabetes Day on November 14, the team from the diabetes information portal diabinfo.de is participating in multiple events to promote knowledge transfer and dialogue around diabetes. Through targeted health information,…

Almost nine million people are living with type 1 diabetes worldwide. Although this disease can be a life-threatening, it often goes unnoticed and is diagnosed too late. Yet type 1 diabetes can be diagnosed early, long before symptoms appear, by a…

Prof. Claudia Traidl-Hoffmann has been reappointed for a second consecutive term to the German Advisory Council on Global Change (WBGU). This reappointment underscores the crucial role of environmental medicine in scientific policy advising. Over the…

The 2024 global Lancet Countdown report on climate change and health underscores that the adverse effects of the climate crisis have reached unprecedented levels worldwide – especially concerning human health. Researchers from Helmholtz Munich…

On October 22, science and culture converged in an exciting collaboration between Helmholtz Munich and the Bergson Kunstkraftwerk. At the inaugural event of the three-part Bergson Academy series, experts from Helmholtz Munich, along with a patient,…

Every year on October 3rd, the German broadcaster WDR organizes the event "Doors Open with The Mouse." This year, 770 companies and research institutions across Germany participated, welcoming children and parents under the theme "Working Together."…

On July 20, 2024, the clever.gesund team from Helmholtz Munich, along with colleagues from the Institute of Medical Imaging and the Human Resources department, showcased their diverse range of services at the Oben Ohne Festival on Munich's…

This summer and fall, Helmholtz Munich will participate in three major community events in Munich: the FORSCHA, the OBEN OHNE Festival, and the Maus Türöffner-Tag. These engagements highlight Helmholtz Munich’s commitment to fostering public interest…

At the third Helmholtz Munich Expert Hour at the German Bundestag on June 4, 2024, the cutting-edge research center provided information on the potential of artificial intelligence (AI) and new technologies to improve medicine in the areas of…

The national diabetes information portal diabinfo.de is expanding its range of information on prevention and now also provides information on diabetes-associated non-communicable diseases.

During the 2nd Helmholtz Munich Expert Hour on April 10, 2024, representatives from politics and science gathered once again to discuss pressing health issues and stay informed about the latest developments in research. The topic "When will diabetes…

Helmholtz Munich organized its first "Expert Hour" in the German Bundestag. With this new event format, Helmholtz Munich will regularly provide information on politically relevant health and research topics in the future and support work in the…

Around two million people in Germany live with diabetes without knowing it. Most often, it's Type 2 diabetes, which develops without symptoms. Test your risk for diabetes now at diabinfo.de. In a few minutes, you will know your personal Type 2…

The consequences of climate change are far-reaching and profound. Extreme weather events, such as heat waves and droughts pose a severe threat to human lives and health.

The national diabetes information portal diabinfo.de will be represented twice this year at the Diabetes Autumn Conference (Diabetes Herbsttagung) of the German Diabetes Association in cooperation with the German Society for Nutritional Medicine in…

Right from an early age, an awareness on health-related topics plays an essential role in preventing diseases and strengthening health. Helmholtz Munich has therefore developed a new health platform together with children and adolescents. The…

The increase in heat periods as a result of climate change can be more critical for people with diabetes than for metabolically healthy people. This is especially true at older ages. The article "Heat and diabetes" from diabinfo.de deals with helpful…

A new ad hoc working group with the topic of “artificial intelligence in medicine” started at the Bavarian Academy of Sciences and Humanities (BAdW). The project is planned for three years and will be executed by the Bavarian Academy of Sciences and…

The national diabetes information portal diabinfo.de provided by Helmholtz Munich, the German Diabetes Center (DDZ) and the German Center for Diabetes Research (DZD) now offers a large number of its services in the areas of "Preventing Diabetes" and…

Numerous renowned female researchers work at Helmholtz Munich. Ensuring that female scientists receive the best support for their careers is an important element in promoting excellence.

With this new campaign, scientists want to raise awareness for early detection and prevention of type 1 diabetes in children.

The campaign “Women@HelmholtzMunich” aims to increase the visibility of women in science and to empower and support women at Helmholtz Munich in their work. With a series of events and social media presence, the campaign will be running between the…

How do I stay healthy? What impact do my environment and lifestyle have on my health? And how can I prevent, treat, or even cure chronic diseases like diabetes, allergies, or lung diseases?

Helmholtz Munich was present at the Superbloom Festival on the 3rd and 4th of September at the Olympiapark grounds in Munich.

The Corona pandemic showed us clearly that to be able to find, understand and evaluate good health information is an important prerequisite for protecting ourselves from fake news. It is therefore important to begin by strengthening the health…

Just in time for World Diabetes Day, the national diabetes information portal www.diabinfo.de has announced that it has expanded its content offering. In addition to German and Turkish, information for people with diabetes and diabetes prevention is…

The "Fit in Gesundheitsfragen" project team at Helmholtz Zentrum München has been awarded the Comenius EduMedia Medal for their e-learning modules on diabetes. The Society for Pedagogy, Information and Media (GPI) awards the medal for outstanding…

For the past decade, Helmholtz Zentrum München has been committed to improving health information and health literacy with its information services. Together with renowned guests from politics and science, the research center discussed the question…

The new Lancet Countdown shows that with a changing climate health risks are increasing globally. The Institute of Epidemiology at Helmholtz Zentrum München together with partners proposed policy recommendations in the Lancet Countdown Policy Brief…